RANIBIZUMAB-EQRN

Anti-VEGF (Ophthalmology)

Brand names: CIMERLI

Intravitreal

Mechanism of Action

12.1 Mechanism of Action Ranibizumab products bind to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110 . VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO. The binding of ranibizumab products to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.

Indications

1 INDICATIONS AND USAGE CIMERLI is indicated for the treatment of patients with: CIMERLI

a vascular endothelial growth factor (VEGF) inhibitor

FDA Warnings

5 WARNINGS AND PRECAUTIONS • Endophthalmitis and retinal detachments may occur following intravitreal injections
• There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors ( 5
• Fatal events occurred more frequently in patients with DME and DR at baseline, who were treated monthly with ranibizumab compared with control ( 5
3 Thromboembolic Events Although there was a low rate of arterial thromboembolic events (ATEs) observed in the ranibizumab clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors

Known Side Effects

2 documented side effects by frequency

Drug Not Working

1-10%

Blurred Vision

1-10%

Community Discussions

No community discussions found for RANIBIZUMAB-EQRN yet.

Compare With

4 available comparisons

Formulations

Dosage Forms

Tablet

Route

Intravitreal